organization · Reporting owner
KPCB XVI Founders Fund, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARMO BioSciences, Inc.
Report date June 22, 2018 · Filed June 22, 2018
Jointly reported with Kleiner Perkins Caufield & Byers XIV, LLC, Kleiner Perkins Caufield & Byers XVI, LLC, KPCB XIV Associates, LLC, KPCB XIV Founders Fund, LLC, KPCB XVI Associates, LLC
Section 16 reporting ended · disclosed 2018-06-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy KPCB Holdings, Inc., as nominee | 0 |
Reported balance
After 2018-06-22 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-06-22 · Other · Disposed 4,266,683 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share. F2: Consists of 3,475,576 shares of common stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). F3: (Continued from Footnote 2) L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share.
F2: Consists of 3,475,576 shares of common stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates").
F3: (Continued from Footnote 2) L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2018 Filed Jun 22, 2018 17:13 UTC | ARMO BioSciences, Inc. ARMO · Entity 12201 | OtherCommon Stock | 4,266,683 | $50.00 | $213,334,150.00 |
DisclosureSEC source: 0000899243-18-017718 · doc4.xml · nonDerivative · entry 1 Kleiner Perkins Caufield & Byers XIV, LLC · CIK 0001505781 · 10% owner Kleiner Perkins Caufield & Byers XVI, LLC · CIK 0001611731 · 10% owner KPCB XIV Associates, LLC · CIK 0001546196 · 10% owner KPCB XIV Founders Fund, LLC · CIK 0001546197 · 10% owner KPCB XVI Associates, LLC · CIK 0001611734 · 10% owner KPCB XVI Founders Fund, LLC · CIK 0001611733 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By KPCB Holdings, Inc., as nominee Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share. F2 · ownership.nature: Consists of 3,475,576 shares of common stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). F3 · ownership.nature: (Continued from Footnote 2) L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. Read SEC document |
| January 30, 2018 Filed Jan 30, 2018 17:05 UTC | ARMO BioSciences, Inc. ARMO · Entity 12201 | ConversionSeries C-1 Convertible Preferred Stock · Derivative | 326,242 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002278 · doc4.xml · derivative · entry 7 Kleiner Perkins Caufield & Byers XIV, LLC · CIK 0001505781 · 10% owner Kleiner Perkins Caufield & Byers XVI, LLC · CIK 0001611731 · 10% owner KPCB XIV Associates, LLC · CIK 0001546196 · 10% owner KPCB XIV Founders Fund, LLC · CIK 0001546197 · 10% owner KPCB XVI Associates, LLC · CIK 0001611734 · 10% owner KPCB XVI Founders Fund, LLC · CIK 0001611733 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By KPCB Holdings, Inc., as nominee Disclosed balance after: 0 Underlying: Common Stock · 326,242 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · derivative.exercise_price: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. F2 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · ownership.nature: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. Read SEC document |
| January 30, 2018 Filed Jan 30, 2018 17:05 UTC | ARMO BioSciences, Inc. ARMO · Entity 12201 | ConversionSeries C Convertible Preferred Stock · Derivative | 403,097 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002278 · doc4.xml · derivative · entry 6 Kleiner Perkins Caufield & Byers XIV, LLC · CIK 0001505781 · 10% owner Kleiner Perkins Caufield & Byers XVI, LLC · CIK 0001611731 · 10% owner KPCB XIV Associates, LLC · CIK 0001546196 · 10% owner KPCB XIV Founders Fund, LLC · CIK 0001546197 · 10% owner KPCB XVI Associates, LLC · CIK 0001611734 · 10% owner KPCB XVI Founders Fund, LLC · CIK 0001611733 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By KPCB Holdings, Inc., as nominee Disclosed balance after: 0 Underlying: Common Stock · 403,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · derivative.exercise_price: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. F2 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · ownership.nature: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. Read SEC document |
| January 30, 2018 Filed Jan 30, 2018 17:05 UTC | ARMO BioSciences, Inc. ARMO · Entity 12201 | ConversionSeries B-1 Convertible Preferred Stock · Derivative | 355,429 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002278 · doc4.xml · derivative · entry 5 Kleiner Perkins Caufield & Byers XIV, LLC · CIK 0001505781 · 10% owner Kleiner Perkins Caufield & Byers XVI, LLC · CIK 0001611731 · 10% owner KPCB XIV Associates, LLC · CIK 0001546196 · 10% owner KPCB XIV Founders Fund, LLC · CIK 0001546197 · 10% owner KPCB XVI Associates, LLC · CIK 0001611734 · 10% owner KPCB XVI Founders Fund, LLC · CIK 0001611733 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By KPCB Holdings, Inc., as nominee Disclosed balance after: 0 Underlying: Common Stock · 355,429 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · derivative.exercise_price: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. F2 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · ownership.nature: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. Read SEC document |
| January 30, 2018 Filed Jan 30, 2018 17:05 UTC | ARMO BioSciences, Inc. ARMO · Entity 12201 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,296,248 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002278 · doc4.xml · derivative · entry 4 Kleiner Perkins Caufield & Byers XIV, LLC · CIK 0001505781 · 10% owner Kleiner Perkins Caufield & Byers XVI, LLC · CIK 0001611731 · 10% owner KPCB XIV Associates, LLC · CIK 0001546196 · 10% owner KPCB XIV Founders Fund, LLC · CIK 0001546197 · 10% owner KPCB XVI Associates, LLC · CIK 0001611734 · 10% owner KPCB XVI Founders Fund, LLC · CIK 0001611733 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By KPCB Holdings, Inc., as nominee Disclosed balance after: 0 Underlying: Common Stock · 1,296,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · derivative.exercise_price: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. F2 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · ownership.nature: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. Read SEC document |
| January 30, 2018 Filed Jan 30, 2018 17:05 UTC | ARMO BioSciences, Inc. ARMO · Entity 12201 | ConversionSeries A Convertible Preferred Stock · Derivative | 1,212,494 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002278 · doc4.xml · derivative · entry 3 Kleiner Perkins Caufield & Byers XIV, LLC · CIK 0001505781 · 10% owner Kleiner Perkins Caufield & Byers XVI, LLC · CIK 0001611731 · 10% owner KPCB XIV Associates, LLC · CIK 0001546196 · 10% owner KPCB XIV Founders Fund, LLC · CIK 0001546197 · 10% owner KPCB XVI Associates, LLC · CIK 0001611734 · 10% owner KPCB XVI Founders Fund, LLC · CIK 0001611733 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By KPCB Holdings, Inc., as nominee Disclosed balance after: 0 Underlying: Common Stock · 1,212,494 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · derivative.exercise_price: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. F2 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · ownership.nature: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. Read SEC document |
| January 30, 2018 Filed Jan 30, 2018 17:05 UTC | ARMO BioSciences, Inc. ARMO · Entity 12201 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 673,173 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002278 · doc4.xml · derivative · entry 2 Kleiner Perkins Caufield & Byers XIV, LLC · CIK 0001505781 · 10% owner Kleiner Perkins Caufield & Byers XVI, LLC · CIK 0001611731 · 10% owner KPCB XIV Associates, LLC · CIK 0001546196 · 10% owner KPCB XIV Founders Fund, LLC · CIK 0001546197 · 10% owner KPCB XVI Associates, LLC · CIK 0001611734 · 10% owner KPCB XVI Founders Fund, LLC · CIK 0001611733 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By KPCB Holdings, Inc., as nominee Disclosed balance after: 0 Underlying: Common Stock · 673,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · derivative.exercise_price: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. F2 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · ownership.nature: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. Read SEC document |
| January 30, 2018 Filed Jan 30, 2018 17:05 UTC | ARMO BioSciences, Inc. ARMO · Entity 12201 | ConversionCommon Stock | 4,266,683 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002278 · doc4.xml · nonDerivative · entry 1 Kleiner Perkins Caufield & Byers XIV, LLC · CIK 0001505781 · 10% owner Kleiner Perkins Caufield & Byers XVI, LLC · CIK 0001611731 · 10% owner KPCB XIV Associates, LLC · CIK 0001546196 · 10% owner KPCB XIV Founders Fund, LLC · CIK 0001546197 · 10% owner KPCB XVI Associates, LLC · CIK 0001611734 · 10% owner KPCB XVI Founders Fund, LLC · CIK 0001611733 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By KPCB Holdings, Inc., as nominee Disclosed balance after: 4,266,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The total represents shares received upon conversion of shares of Series A-1, A, B, B-1, C and C-1 Convertible Preferred Stock. F2 · price: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · ownership.nature: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.